Information about molecules and research questions. Studies do not certify a commercial product or tell you what to use.
Tirzepatide
The short explanation
SURMOUNT-4 asks a maintenance question. People entering the comparison had already received the intervention for 36 weeks.
What is being researched?
Was the weight lost maintained when treatment continued or when participants switched to placebo?
What does this mean for you?
The placebo-switch group regained weight on average. This describes the trial; it is not an instruction to start, continue or stop treatment.
What we cannot be sure of
The comparison selected people who tolerated the initial phase. Digestive symptoms matter, and the findings certify neither a supplier product nor its authorization in Mexico.
This information does not tell you whether a product is right for you. If you use it or are considering it, discuss your questions and possible risks with a healthcare professional.
What can a quality report tell you?